$186 Million

SpringWorks Therapeutics, Inc.

Initial Public Offering

Bookrunner, September 2019

SpringWorks Therapeutics, Inc.
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing and commercializing life-changing medicines for underserved patient populations suffering from devastating rare diseases and cancer. The Company has a differentiated portfolio of small molecule targeted oncology product candidates and are advancing two potentially registrational clinical trials in rare tumor types, as well as a number of other programs addressing highly prevalent, genetically defined cancers. The Company’s most advanced product candidate, nirogacestat, is an oral, small molecule gamma secretase inhibitor (GSI) initially in development for the treatment of desmoid tumors. The Company’s second product candidate is mirdametinib, an oral, small molecule MEK inhibitor initially in development for the treatment of NF1-PN, a rare tumor of the peripheral nerve sheath.